Significant Ownership of Bellevue Group AG

Signature - Title
/s/ Stefano Montalbano - Stefano Montalbano/ Chief Financial Officer
Location
Zurich
Summary
This page shows a list of all the recent SCHEDULE 13D/G filings made by Bellevue Group AG.

Follow Filing Activity

Follow Bellevue Group AG and return when a new Schedule 13D/G filing changes the record on this page.

This uses the existing product follow flow to surface future filing-backed changes without guessing what they mean.

Significant Ownership of Bellevue Group AG

Sym Company Class Ownership Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
JBIO Jade Biosciences, Inc. Common Stock 6.8% $46,307,688 3,341,103 Bellevue Group AG 16 Dec 2025
IMCR Immunocore Holdings plc Ordinary shares 5.6% $101,607,853 2,796,803 Bellevue Group AG 20 Aug 2025
CLDX Celldex Therapeutics, Inc. Common Stock 5.4% $93,589,097 3,617,669 Bellevue Group AG 18 Aug 2025
MGNX MacroGenics, Inc. Common Stock 0% $0 -$13,901,948 0 -100% Bellevue Group AG 05 Dec 2025
AGIO Agios Pharmaceuticals, Inc. Common Stock 0% $0 -$142,398,726 0 -100% Bellevue Group AG 19 Nov 2025

Schedules 13D/G Reported by Bellevue Group AG:

Sym Target Class Ownership Change Current Shares Change Value Reporting name Form Report Period Filing Date
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .